|
Oct 9
|
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...
|
|
Jul 29
|
HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
|
|
Jun 26
|
HUTCHMED to Announce 2024 Half-Year Financial Results
|
|
Jun 24
|
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
|
|
Jun 21
|
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
|
Mar 28
|
Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?
|
|
Mar 28
|
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
|
|
Jan 11
|
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
|
|
Dec 1
|
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
|
|
Aug 29
|
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
|